Pfizer Inc
NYSE: PFE
$25.77
-$0.40 (-1.5%)
Closing Price on November 26, 2024
PFE Articles
Pfizer is scheduled to release its fourth-quarter financial results before the markets open on Tuesday. Consensus estimates call for modest year-over-year growth.
Published:
Last Updated:
The January 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
24/7 Wall St. has put together a preview of those Dow Jones industrials scheduled to report their quarterly results this week, including Apple, Exxon and Microsoft.
Published:
Last Updated:
24/7 Wall St. has ranked these Dow Stocks on their performance thus far in 2019, as of Wednesday’s closing price. We have also added in some additional color on these companies as well.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amazon.com, Dell Technologies, IBM, International Paper, Merck, Pfizer, Tesla, Teva Pharmaceutical and...
Published:
Last Updated:
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
See why preliminary 2019 consensus-based forecasting has offered up a likely target of 28,000 on the Dow Jones industrial average in 2019.
Published:
Last Updated:
Investors love their dividends. So 24/7 Wall St. has tracked the Dogs of the Dow strategy for years now.
Published:
Last Updated:
The December 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
These six safer stocks all carry Merrill Lynch’s best volatility risk rating and pay dependable dividends. They offer reasonable entry points too.
Published:
Last Updated:
GlaxoSmithKline shares bounced higher on Wednesday after the company announced a new joint venture with Pfizer. These two firms will create a premier global consumer health care company combining...
Published:
Last Updated:
Elon Musk previews Los Angeles transportation tunnel, Pfizer and GlaxoSmithKline team up, stock buybacks hit a record this year, and other important business headlines today.
Published:
Last Updated:
These six Buy-rated stocks that have had a strong year and would be solid additions to portfolios for the end of 2018 and the beginning of 2019.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
The included top analyst upgrades, downgrades and initiations seen on Tuesday Apptio, AT&T, Bain Capital, Comerica, First Solar, Palo Alto Networks, Pfizer, Travelers and Ulta Beauty.
Published:
Last Updated: